by secretome | Apr 23, 2025 | News
DALLAS–(BUSINESS WIRE)–Secretome Therapeutics, a clinical-stage biotechnology company pioneering therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced the appointment of Marshelle Smith Warren, MD, as Chief Medical Officer. Dr....
by secretome | Mar 25, 2025 | News
PLANO, Texas & BALTIMORE–(BUSINESS WIRE)–Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced dosing of the first patient in its Phase 1...
by secretome | Mar 20, 2025 | News
DALLAS–(BUSINESS WIRE)–Secretome Therapeutics, a pioneering company in the field of regenerative medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to STM-01, the company’s neonatal cardiac...
by secretome | Jan 22, 2025 | News
THE WOODLANDS, Texas and DALLAS, Jan. 22, 2025 /PRNewswire/ — Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome Therapeutics, a biotechnology company advancing...
by secretome | Nov 25, 2024 | News
DALLAS–(BUSINESS WIRE)–Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced the successful closing of a $20.4 million round of financing. This funding will enable...
by secretome | Oct 28, 2024 | Investors, News
DALLAS–(BUSINESS WIRE)–Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced the allowance of a composition of matter patent for its lead asset, STM-01, a novel nCPC...
by secretome | Sep 17, 2024 | News
DALLAS, Sept. 17, 2024 /PRNewswire/ — HEST Investments, a Dallas-based venture capital family office renowned for its focus on innovative and bleeding edge ventures, proudly announces its successful SPV (Special Purpose Vehicle) of...
by secretome | Jul 18, 2023 | News
DALLAS–(BUSINESS WIRE)–Secretome Therapeutics, a biotechnology company developing first-in-class therapeutics from neonatal mesenchymal stem cells (nMSC) today announced the appointment of Margot Connor to its Board of Directors. “Margot’s unparalleled...
by secretome | May 16, 2023 | Investors, News
[DALLAS, TX – May 12, 2023] — Secretome Therapeutics, a pioneering biotechnology company focused on developing regenerative cell therapies, is pleased to announce its participation in the prestigious ISSCR 2023 Annual Meeting, held at the Boston Convention and...
by Sudhish Sharma | Jun 17, 2022 | Journals, Uncategorized
Abstract Gunasekaran et al demonstrate that human neonatal Mesenchymal Stem Cells (nMSCs) evade from macrophage mediated phagocytosis via increased CD47 expression and to promote functional recovery by secretion of exosomes and independent cytokines. The increased...
